Antag Therapeutics
PrivateLast Round
Series A
Dec 4, 2024
Total Funding Raised
$90M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Antag Therapeutics is a biopharmaceutical company that develops peptide-based GIP receptor antagonist therapies for obesity and cardiometabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antag Therapeutics Comparables
Compare Antag Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ousia Pharma | 82% | |
| Alveus Therapeutics | 80% | |
| Pep2Tango Therapeutics Inc. | 74% |
Antag Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 4, 2024 | ||||
| Seed | Jun 26, 2017 | ||||
| Seed | Apr 1, 2017 |
Key People
Founding team and executive leadership
Antag Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pictet Group | Series A |
| Viva Biotech | Series A |
| Versant Ventures | Series A |
| Novo Holdings | Series A, Seed |
| The Export and Investment Fund of Denmark | Series A |
| SR One | Series A |
| Longview Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 109% MoM, reaching 3.8K.
- Apr 23, 2026
Presenting at the American Diabetes Association Scientific Sessions in June 2026.
Recent news
Latest coverage and updates
- is_developingJul 28, 2026
Antag Therapeutics ApS will develop AT7687 on Jan 1st '27.
Antag Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Antag Therapeutics's valuation, stock price, and market status.
Is Antag Therapeutics a public or private company?
Antag Therapeutics is a private company.
What is the current stock price of Antag Therapeutics?
Antag Therapeutics is a private company, so its shares have no public market price. Caplight tracks Antag Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antag Therapeutics worth (valuation)?
Valuation information for Antag Therapeutics is not publicly available.
Can I buy Antag Therapeutics stock?
Antag Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antag Therapeutics's last funding round?
Antag Therapeutics's most recent funding round was Series A on December 4, 2024.
Who are the main investors in Antag Therapeutics?
Key investors in Antag Therapeutics include Versant Ventures, Novo Holdings.
Will Antag Therapeutics IPO soon?
No public IPO plans have been announced for Antag Therapeutics.
How can I track Antag Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Antag Therapeutics's shares on secondary markets.